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Abstract 
Studies of non-human animals have provided ample evidence that opioids are involved in reward 
processes. Less is known about the role of the opioid system for human reward processes. We 
hypothesized that an opioid agonist would increase, and an opioid antagonist would decrease 
responsiveness to rewards in healthy humans. We tested 30 healthy male participants on a reward 
responsiveness task using a randomized, placebo-controlled double-blind design. Participants 
received oral treatment with a µ-opioid agonist (morphine, 10mg), a non-selective opioid 
antagonist (naltrexone, 50mg) or placebo on three separate days. One-two hours after drug 
administration, one of three locally developed versions of a reward responsiveness task was 
completed. The task was a two-alternative signal detection task with a skewed reward schedule. 
Stimuli were schematic faces which differed in the size or position of the mouth. Reward 
responsiveness was operationalized as a bias towards choosing the most frequently rewarded 
response option. In line with our hypothesis, the results showed that morphine significantly 
increased and that naltrexone significantly decreased bias relative to placebo. These effects could 
be due to either a direct effect of opioid agonism/antagonism on the neural reward system, or due 
to indirect effects, e.g. via opioid effects on striatal dopamine functioning. Notably, although our 
naltrexone condition would be expected to block endogenous opioid function, reward 
responsiveness was not completely eliminated. This could indicate that opioids may be involved 
in, but not necessary for, this effect. Overall, our findings confirm a role for the opioid system in 
human reward responsiveness.  
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Introduction 
The events and objects that motivate human beings to act are many. Whether they pull us towards 
something or push us away, these are at the heart of things that govern our behaviour. Reward 
can be defined as “(…) anything for which an animal will work” (Rolls, 2006, p. 3). The term 
positive reinforcer is closely related to reward, but refers specifically to an event in which a 
response is followed by a stimulus and the probability for that response increases (Skinner, 
1938). This stimulus is consequently defined as appetitive. The terms reward and positive 
reinforcer will be used interchangeably in this thesis.  
A variety of different stimuli constitute positive reinforcers to animals and human beings. 
Some of these are rewarding without prior exposure or learning (primary/unconditioned 
reinforcers); other stimuli can acquire a positive value via its link to a primary reward, e.g. money 
and other tokens (secondary/conditioned reinforcers) (Dinsmoor, 2004; Skinner, 1938). The 
reinforcing value of a stimulus depends on the state of the individual and the properties of the 
stimulus itself (Berridge & Kringelbach, 2008). For instance, the value of food for an organism at 
a given time depends on whether food is abundant, or sparse (Small, Zatorre, Dagher, Evans, & 
Jones-Gotman, 2001). Many other aspects of the reward, or the environment, can affect the 
reinforcing value of a stimulus, such as the palatability of a type of food, or the safety of the 
environment (Rolls, 2005; Stevenson, Bilsky, & Negus, 2006) 
Advances in affective  neuroscience over the last decades have unravelled a range of partly 
dissociable and highly interrelated phenomena that constitute, and support, reward processing in 
humans and animals (Berridge & Kringelbach, 2008; Kelley, 2004). Berridge has divided the 
reward construct into three subcomponents (Berridge & Robinson, 1998; Berridge, Robinson, & 
Aldridge, 2009): (1) ‘Liking’, which refers to the positive affective response to a rewarding 
stimulus;  (2) ‘Wanting’, which describes the motivation to obtain, ‘work for’, and approach 
rewarding stimuli;  and (3) Learning, which entails obtaining and integrating reward relevant 
knowledge that allows for prediction of reward events, and updating this information as new 
information becomes available.  ‘Wanting’, ’liking’ and learning may be subconscious processes, 
or explicitly experienced by the agent (Berridge, 2007). Notably, in ecological situations positive 
reinforcers are normally both liked and wanted, and stimulate learning and anticipation (Barbano 
& Cador, 2007; Berridge & Kringelbach, 2008; Smith, Berridge, & Aldridge, 2011). However, 
during the last decades, evidence has accumulated to support the notion that different interrelated 
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neurotransmitter systems and networks of brain regions contribute to the different aspects of 
reward (Kranz, Kasper, & Lanzenberger, 2010). Dissociating these have been a major concern in 
neuroscience research on reward-related phenomena (Berridge et al., 2009; Der-Avakian & 
Markou, 2012).  
 
The neuroscience of reward 
One of the first research findings that inspired the study of neurobiological correlates of  
reward mechanisms came from an experiment conducted by Olds and Milner (1954), in which 
rats with electrode implants were observed in a Skinner box. The rats were given the opportunity 
to self-administer electric stimulation to a certain brain area by pressing a lever. The researchers 
reported that electric stimulation to many areas in the “lower centres of the brain” appeared to be 
very rewarding to the subject, measured by the frequency of subsequent lever presses (Olds & 
Milner, 1954, p. 426). The areas that correlated with reinforcement behaviour have later been 
identified as striatal areas (Berridge, 2007). By the use of a wide variety of methods, the neural 
underpinnings of reward-related processes have been studied vigorously ever since (Haber & 
Knutson, 2010).This has led to a better understanding of the biological substrates of motivated 
behaviour, and valuable knowledge that has been used to develop treatments for drug addiction 
and dependence. However, there are still many unanswered questions in regards to reward-related 
behaviour and experience (Der-Avakian & Markou, 2011).  
 Much of what is known about the neural underpinnings of reward processes has been 
derived from non-human animal research, often using palatable food as positive reinforcer. There 
are advantages of using animal subjects in this type of research; it allows scientists to use strict 
experimental control the animal’s environment and stimulus exposure over an extended period of 
time. In addition to behavioural measures such as indexes of effort, preference towards a stimulus 
and stimulus reactivity, several methodologies allow for detailed investigation of the underlying 
neural processes of animals reward behaviour.   
Intracranial self-stimulation (ICSS) is used to assess the motivation behaviour an animal 
has to stimulate regions in its own brain with electricity or substances. Single neuron recording is 
used in animal research and can inform us about neural activity on a very small scale in real-time 
(e.g. Roesch, Singh, Brown, Mullins, & Schoenbaum, 2009). Animal reward researchers also use 
direct microinfusions of neuromodulating substances into specific brain regions to look for area-
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specific functions of the substances in question (e.g. Peciña & Berridge, 2005).  Microdialysis 
and voltammetry are methods that allow for in vivo analysis of extracellular neurotransmitter 
levels on a very small scale (see Marsden, 2006).  In addition to these methods, genetic knock-out 
(KO) studies have become available in animals. These permit manipulation of the availability of 
different neurotransmitters via genetic alterations which may reveal functional correlates of 
neurotransmitters (e.g. Hnasko, Sotak, & Palmiter, 2005). The methods used in animal research 
provide a level of detail and control still unobtainable in human research; this literature has also 
guided studies on the human reward system. 
The question remains of how much of the results from these studies can be generalized to 
humans. Some research indicates that there are commonalities between the reward systems in 
human and other mammal brains (Haber & Knutson, 2010; Kringelbach & Berridge, 2009; 
McClure, York, & Montague, 2004) (see Figure 1 for an illustration of the reward circuits in the 
rodent and human brain. Nevertheless, because the methods available for studying human neural 
systems are more limited this relationship still remains somewhat elusive.  The animal research 
finding on reward-related behaviour has to some extent been replicated, and complemented, in 
recent years by neuroimaging studies with human subjects (Porcelli & Delgado, 2009). Studies 
using human participants also allow us to look at the involvement in complex brain areas (that are 
less frequently studied in animal research) and to study more abstract, aesthetic and social 
rewards. In addition, human participants may report on the subjective experience of positive 
reinforcers, which is important in order to understand the relationship between brain activity, 
behavioural measures and hedonic experience. Nevertheless, there are important strengths and 
weaknesses to the methods available for studying reward processing in the human brain. 
Functional magnetic resonance imaging (fMRI) and  Positron Emission Tomography (PET) are 
currently the neuroimaging methods of choice in the study of reward related phenomena 
(McClure et al., 2004). While fMRI blood-oxygen level-dependent (BOLD) signal is believed to 
reflect energy usage and ultimately neural activity in the brain (Logothesis, 2003), PET can 
provide information about receptor occupancy of neuromodulators (Spreckelmeyer et al., 2011). 
Both these methods offer  temporal resolutions much slower than the specific neural events 
causing the activity measured, but have been much used in recent years in this line of research 
(Boecker et al., 2008; Ernst et al., 2004; Kringelbach, O'Doherty, Rolls, & Andrews, 2003; 
McClure et al., 2004; Pizzagalli et al., 2009; Porcelli & Delgado, 2009). The temporal and spatial 
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restrictions limit the inferences that can be made on the basis of neuroimaging results. While 
fMRI and PET may provide information about primary regions of activity associated with a 
stimulus or behaviour, the range of neurotransmitters involved and whether the neural activity is 
excitatory or inhibitory remains unknown. Electroencephalography (EEG) is less used in reward 
research, due to the difficulty in localizing the origin of electric activation in deeper regions of 
the brain. However, event-related fMRI, combining the resolution advantages of fMRI and EEG, 
is emerging as a viable method for studying reward-related activity in the brain (McClure et al., 
2004). 
 
The use of systemic pharmacological manipulation is also a viable option for studying 
causal relationships between neurotransmitter activity and behavioural, affective and cognitive 
measures in humans and animals (Rogers, 2011). This method allows us to stimulate, reduce or 
block the workings of endogenous neural modulators. Psychopharmacological studies can 
Figure 1. Displaying reward related brain areas in the rodent and human brain. The figure is adapted 
from Kringelbach and Berridge (2009). In addition to these regions, the substantia nigra (SN), 
hippocampus (HC), ventromedial prefrontal cortex (vmPFC) and some brainstem areas have also been 
implicated in  human and animal reward studies (Haber & Knutson, 2010).  
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potentially provide knowledge about which transmitter systems that are necessary for a certain 
psychological processes, and which transmitters that are involved in it, by blocking and 
stimulating endogenous neural transmission. Importantly, the neural mechanisms through which 
the substances work cannot be elucidated by this method alone because, for the time being, we 
cannot monitor or locally control neurotransmission like we can do in animal subjects. However, 
inferences can be made based on findings from animal and human reward research. Triangulating 
research from different methods or combining several methodologies (e.g. pharmacological 
fMRI), is perhaps the best chance we have of elucidating the neural substrates of the human 
brain.  
Dopamine reward.  Through the use of diverse methodologies, a complex interaction of 
many brain regions involved in reward has been revealed (Kelley, 2004; O'Doherty, 2004). 
Figure 1 displays some of the most commonly implicated brain regions in reward research, both 
in humans and animals (Kelley, 2004; Kelley & Berridge, 2002; Kringelbach, 2005; Rolls & 
Xiang, 2005; McClure et al., 2004; O'Doherty, 2004; Peciña & Berridge, 2005).  
A significant portion of the relatively few areas of dopaminergic neurons in the brain are 
located in the brain areas referred to in figure 1 (Björklund & Dunnett, 2007). More than any 
other neurotransmitter system, dopamine (DA) has been the key suspect for reward processes 
(Schultz, 2002). DA appears to be important for reward processes that are linked to both primary 
and drug reinforcers (Nestler, 2005). There is now ample evidence that DA is has a central role in 
processes such as anticipation of reward, motivated behaviour (‘wanting’) and reward learning 
(Daw, 2007; Der-Avakian & Markou, 2012; Kelley, 2004; Salamone, 2007; Schultz, 2007; 
Sugam, Day, Wightman, & Carelli, 2012; Tobler, Fiorillo, & Schultz, 2005). In particular, the 
midbrain DA pathways have been suggested to play a crucial role in reward processing (Barbano 
& Cador, 2007; Berridge, 2012; O'Doherty et al., 2004). 
The ventral tegmental area (VTA) and substantia nigra (SN) are key DA producing nuclei, 
both located in the midbrain, these project to many other brain regions (Björklund & Dunnett, 
2007). The axons of DA neurons in the SN project to the caudate and putamen in the dorsal 
striatum, forming the mesostriatal (or nigrostriatal) DA pathway while dopaminergic axons in the 
VTA project both to the NAc in the limbic system also called the mesolimbic DA pathway, and 
to the prefrontal cortex, forming the mesocortial DA pathway (Björklund & Dunnett, 2007). 
Among these, it is primarily the mesolimbic pathway that has been implicated in reward studies. 
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This pathway will receive a primary focus in this thesis although the mesostriatal and 
mesocortical pathways have also received attention in relation to motivated behaviour (e.g. 
Marsden, 2006; Palmiter, 2008).  
The nucleus accumbens (NAc) and the VTA are key regions in the mesolimbic dopamine 
reward circuitry (Haber & Knutson, 2010). This network has received considerable interest in 
research on reward-related mechanisms, related to both primary and drug reinforcers (Baldo & 
Kelley, 2007; Chefer, Denoroy, Zapata, & Shippenberg, 2009; Iordanova, 2009; Nestler, 2005; 
Palmiter, 2008; Smith & Berridge, 2007).  It has been proposed that the NAc integrates many 
types of reward related input from different brain areas, such as affective information from the 
amygdala and homeostatic information from the hypothalamus, in order to control reward-related 
behaviour (Kelley, 2004).  
Single cell recordings of dopaminergic neurons in animals have demonstrated that DA 
transmission has several time courses.  Tonic steady firing and  transient phasic bursts of 
increased firing (Schultz, 2010).  It is in particular the phasic activity of midbrain DA neurons 
that have been implicated in response to external salient and rewarding stimuli (Schultz, 2010). 
These typically follow a stimulus by 60-200 milliseconds, and have been suggested to code 
reward value as it differs from prediction, namely the prediction error (Schultz, 2007). Evidence 
for phasic DA transmission during anticipation and learning of rewards was provided in a study 
by Ljungberg and colleagues (Ljungberg, Apicella, & Schultz, 1992). In this experiment transient 
DA neuron firing was studied in monkeys using single-cell recordings. The results showed 
transient increases in DA cell firing during reward administration in the stimulus-response 
learning, but only in response to the cue predicting reward after learning the task. The VTA-NAc 
complex has also been implicated in the prediction error signal (Iordanova, 2009). Dopaminergic 
projections to the dorsal striatum appear to play an important role in stimulus-response-reward 
associations (Montague, Dayan, & Sejnowski, 1996), and DA is involved the process in which 
incentive salience is assigned to reward cues in particular (Flagel et al., 2011). NAc DA 
involvement in reward prediction error and reinforcement learning received additional support in 
a recent study by  Sugam et al. (2012). Fast-scan cyclic voltammetry
1
 was used to measure NAc 
                                                 
1
 An electrochemical technique that can be used to monitor release and uptake dynamics of 
endogenous dopamine, serotonin , and noradrenaline in vivo and in vitro (John & Jones, 2007).   
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core DA activity in rodents, during a risky choice decision task. The authors found that all cues 
predicting a reward elicited increased DA release in the NAc. 
In regards to human homologues, a recent review of psychopharmacological research on 
DA and decision making lends support to the notion that dopamine also plays a crucial role in 
value-based decision making and reinforcement learning in humans (Rogers, 2011). Further, in a 
fMRI experiment conducted by Knutson and Wimmer (2007) reward prediction and reward 
prediction error were modeled separately, these were found to correlate with BOLD activity in 
the medial prefrontal cortex and NAc respectively. Both these regions are targets for dopamine 
projections from the VTA, suggesting dopaminergic involvement (Knutson & Wimmer, 2007). A 
study of patients with Parkinson’s disease (a disease directly linked to NS dopamine deficit) by 
Frank, Seeberger, and O'Reilly (2004) revealed a special role for DA in learning from positive 
reinforcement (as opposed to negative reinforcement).  
Many studies support a role for DA as a causal factor in reinforcement learning, and phasic 
dopamine involvement prediction error coding. However, these are still topics of hot debate 
(Berridge, 2007; Robinson, Sandstrom, Denenberg, & Palmiter, 2005).  
Is dopamine necessary for all reward processes? The ‘DA hypothesis of reward’ has 
dominated the research on reward to the extent that there might be a research bias towards DA 
functioning in the related neuroscience literature (Salamone & Correa, 2002; Salamone, 2007). 
Dopamine was thought to directly mediate all reward functions, including the mediation of the 
pleasurable (‘liking’) properties of rewarding stimuli (Koob & Moal, 1997; Salamone, 2007; 
Wise, 1982). However, during the last decades, this idea has been challenged by several 
researchers and findings from experimental research (Berridge & Robinson, 1998; Smith et al., 
2011). Results from studies on ingestive behaviour suggest that the pleasure element of reward 
(‘liking’) is mediated mainly by the µ-opioid system, rather than dopaminergic circuit. (see 
reviews by Baldo & Kelley, 2007; Berridge et al., 2009).  This notion receives support from 
studies demonstrating that dopamine antagonism fails to reduce food intake, whereas direct 
infusions and systemic administration of µ-opioid receptor (MOR) agonists increase food intake 
(Bodnar, 2004). Another line of evidence supporting a key role of µ-opioids for positive affect in 
reward (‘liking’) comes from research seeking to make objective measures of ‘pleasure-
behaviour’ in different animals. Although pleasure as a concept is often understood as an 
experienced subjective state, some research indicates that pleasure can be measured in animals 
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and non-verbal humans (infants) by analysing cross-species equivalents in body reactions to 
appetitive stimuli (Berridge, 2007). Common denominators in how humans and other animals 
(e.g. apes and rodents) act when presented with a natural reward such as sucrose (Berridge, 
2000), enable researchers to investigate homologous affective reactions across species. Positive 
taste reactivity is significantly increased by opioid manipulation, in particular by direct infusion 
of agonists to the NAc (Peciña & Berridge, 2000; Peciña, Smith, & Berridge, 2006).  
Regarding evidence implicating opioids in human reward, µ-opioid receptor binding has 
been found to correlate with the euphoria associated with physical activity  (’runner’s high’) 
(Boecker et al., 2008).  Also, opioid antagonism has been found to reduce the pleasantness of 
food (Yeomans & Gray, 1996),  the pleasurable effects of amphetamine (Jayaram-Lindström, 
Wennberg, Hurd, & Franck, 2004) and the euphoria associated with runner’s high in humans The 
opioid system may also mediate the pleasure associated with alcohol and nicotine (Hnasko et al., 
2005; Oslin et al., 2003).  
In addition, some animal research indicate that positive reinforcement from food and is 
not completely dependent on DA functioning. Cannon and Palmiter (2003) tested sucrose naïve 
mice, that could not produce their own dopamine (knockout mice), with a sucrose reward task. 
They found the DA deficient (DD) mice, alike the control mice, preferred a sucrose solution to 
water. Based on previous ingestion and taste studies, the authors interpret this preference to be 
mediated by opioids rather than DA (Cannon & Palmiter, 2003).Results from this study indicate 
that dopamine may not be necessary for preferring a natural reward. Further, Hnasko et al. (2005) 
investigated the rewarding effects of morphine in DA deficient mice using a place-preference 
paradigm. They found that even though the morphine-associated hyperlocomotion associated 
with reward was attenuated, it was not eliminated in mice unable to produce endogenous 
dopamine. 
Together these findings speak for a central role of opioids in mediating the affective 
aspect of reward (‘liking’). Evidence for the involvement of a second neurotransmitter in reward-
related processes, namely opioids, implies that some reward mechanisms may be supported by 
interactions of these two neuromodulators, a notion that has received solid support through 
animal research.  
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The link between opioids and dopamine in reward mechanisms.  Opioid and dopamine 
systems interact during reward-related processes (Burkett, Spiegel, Inoue, Murphy, & Young, 
2011; Spreckelmeyer et al., 2011). There is now ample evidence that opioid manipulation, either 
systemic or injected directly into striatal areas, can modify DA activity in the NAc of rodents 
(Maisonneuve, Warner, & Glick, 2001; Spanagel, Herz, & Shippenberg, 1992; Vindenes et al., 
2009). One interpretation of these findings is that opioids can modulate the amount of DA 
released in response to a certain rewarding stimulus (Nestler, 2005). This mechanism may be 
mediated by GABA-containing interneurons (γ- aminobuatric acid) in the VTA, as shown in an in 
vitro rodent study by Johnson and North (1992). Tonic GABAergic activity in the VTA inhibits 
dopaminergic signal transmission to the NAc (Nestler, 2005). The idea is that opioid 
manipulation will excite or inhibit GABAergic interneurons in the VTA, which further leads to 
dopaminergic NAc activity (see Figure 2).  Johnson and North (1992) also reported that it was 
mainly the µ-opioid receptors (MOR) that mediated this effect. MOR agonists such as morphine 
and heroine can disinhibit these GABAergic cells consequently increasing phasic DA signalling 
to the NAc (Chefer et al., 2009). It has been postulated that opioid antagonists such as naltrexone 
or naloxone induce an opposite pattern (e.g. Nathan & Bullmore, 2009), namely a MOR blockade 
increasing the inhibitory 
transmission of GABAergic neurons, 
leading to reduced DA transmission 
in the NAc. Also, Spanagel et al. 
(1992) demonstrated that MOR 
agonism in the VTA increase DA  
release in the NAc whereas the 
blockade of MORs results in a 
decrease in DA release in rodents. 
Notably, DA increase was not found 
when injecting this agonist directly 
into the NAc, speaking for an 
indirect effect of µ-opioids on 
dopaminergic acitivty in the NAc. 
Figure 2. An illustration of the dopamine-opioid interaction in 
the VTA-Nac network. Adapted from Nestler, 2005. 
Nature Neuroscience.  
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As for systemic opioid manipulation,Vindenes et al. (2009) found increased levels of DA in the 
NAc of rodents following a morphine injection.  
Less is known about a possible opioid-DA VTA-NAc mechanism in human beings. 
However, some indirect evidence, mainly from drug addiction research, suggests that this 
network and its functions can be found in human beings as well. Addictive behaviour related to 
both psychostimulant drugs and natural rewards diminish during opioid antagonist treatment 
(Bachs & Waal, 2003; Brauer, Behm, Westman, Patel, & Rose, 1999; Drewnowski, Krahn, 
Demitrack, Nairn, & Gosnell, 1995). One example of opioid-dopamine-interaction in human 
beings is found in a study conducted by Jayaram-Lindström and colleagues on healthy non drug-
abusing men (2004). They studied the effect of naltrexone (50 mg) on the subjective, 
physiological and cognitive effects of amphetamine, a drug known to exert its effects on the DA 
system (2004). The authors reported a significant attenuation of the subjective effects of 
amphetamine, such as ratings of drug ‘high’ and drug liking, in the naltrexone condition 
compared with placebo. Also, µ-agonism increases endogenous DA levels (Spreckelmeyer et al., 
2011).  Taken together, these studies make a good case for a possible interaction of DA and 
opioids in reward related neurotransmission in both humans and non-human animals. 
  
The Current Study 
The ability to alter behaviour in order to obtain a reward is adaptive (O'Doherty et al., 
2004). Being sensitive to reinforcement helps an organism in determining appropriate behaviour 
for fulfilling primary and secondary needs. The lack of this behaviour is associated with 
psychopathology, e.g. major depression, eating disorders and schizophrenia (Gorwood, 2008; 
Schultz, 2007). Asymmetric reward schedules can induce systematic biases in sensorimotor 
choices. This bias is sometimes termed ‘reward responsiveness’, and can be defined as the degree 
to which behaviour is modulated as a function of positive reinforcement. This process requires 
integrating reinforcement history over time (Gorwood, 2008). The evidence for opioid 
involvement in the affective aspects of natural rewards taken together with studies showing 
opioid-dopamine interaction in the VTA-NAc network, led us to hypothesize that systemic opioid 
agonism and antagonism would modulate reward responsiveness.  
One parsimonious paradigm that has been used to study the degree to which behaviour is 
modulated as a function of rewards received in human beings is based on signal-detection 
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methodology. The task requires a participants to indicate which of two ambiguous schematic face 
stimuli (S1 or S2) that has been presented by making the appropriate response (B1 or B2, 
respectively) (Tripp & Alsop, 1999). Unknown to the participant, the ratio of reward outcome for 
correct B1 and B2 responses used in this task is skewed, so that correct B1 is rewarded three 
times more frequently than correct B2. This paradigm provides an objective laboratory measure 
of behaviour modification as result of positive reinforcement. Healthy participants ordinarily 
show a clear response bias towards the more frequently rewarded stimuli (e.g. Pizzagalli et al., 
2009). This reward responsiveness bias has been replicated in a range of diverse contexts, 
including studies with different patient groups, psychopharmacological studies and neuroimaging 
studies (Barr, Pizzagalli, Culhane, Goff, & Evins, 2008; Bogdan & Pizzagalli, 2006; Pizzagalli, 
Evins, et al., 2008; Pizzagalli, Goetz, Ostacher, Iosifescu, & Perlis, 2008; Pizzagalli, Iosifescu, 
Hallett, Ratner, & Fava, 2008; Pizzagalli, Jahn, & O'Shea, 2005; Tripp & Alsop, 1999).  
Neuromodulators for Reward Responsiveness.  Some research has been conducted in 
order to understand the neuromodulatory underpinnings of human reward responsiveness. For 
example, there is evidence for involvement of dopaminergic transmission. A very small dosage of 
the DA agonist, pramipexole acts as antagonist on the phasic DA response and caused reduced 
reward responsiveness (Pizzagalli, Evins, et al., 2008). Compared to the placebo control group, 
the pramipexole group showed reduced reward learning. Further, Pizzagalli and colleagues have 
employed the same task in a PET study to investigate endogenous DA release in relation to 
reward responsiveness (Vrieze et al., 2011). The authors found indirect evidence for endogenous 
dopamine release in the OFC, anterior CC and ventromedial prefrontal cortex associated with 
reward responsiveness.  
One recent study has begun to address the question of opioid involvement in reward 
responsiveness in humans. This study was conducted recently by Lee and colleagues (2011), and 
investigated the role of two polymorphisms of the mu-opioid receptor (MOR) gene OPRM1 in 
reward responsiveness, applying the task used by Pizzagalli and colleagues. The results of this 
study showed that carriers of specific gene variant, G allele carriers, displayed reduced reward 
responsiveness. Carriers of the most common variant of the OPRM1-gene (AA homozygotes) 
showed typical reward responsiveness. 
To measure reward responsiveness in the present study we employed the same behavioural 
paradigm used in the studies described in the previous paragraph, with some modifications. This 
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paradigm provides an index of behaviour modification as a function of rewards received, and is 
suitable for evaluating how drugs affect our reactions to external stimuli (Wardle & de Wit, 
2012). Based on research indicating a dopamine-opioid interaction in reward processes and recent 
studies implicating a role of DA in reward responsiveness, we hypothesized that: Systemic opioid 
manipulation would alter reward responsiveness in healthy participants. More specifically we 
hypothesized that: 
a) A µ-opioid receptor agonist, morphine, would lead to increase in reward responsiveness 
compared to a placebo control condition. 
b) A non-selective opioid antagonist, naltrexone, would reduce reward responsiveness 
compared to a placebo control condition.  
 
Methods and Materials 
Participants 
We recruited 30 healthy male volunteers for this study. Two participants were excluded 
from analysis: one tested positive on the opiate urine screening, the other participant only 
completed one session. The final number of participants was 28, aged 20 to 36 years (M = 26.7, 
SD = 4.7 years, 26 right-handed). In a pre-testing telephone screening interview, none of the 
participants reported a history of depression or other major psychiatric illness, none were 
currently suffering from psychiatric or medical illness, none were currently on medication and 
none had multiple complex allergies. None of the participants reported prior drug dependence or 
addiction. All participants were morphine naïve, i.e. had not taken morphine in any form for at 
least two years prior to testing (Becerra, Harter, Gilberto Gonzalez, & Borsook, 2006). 
Participants had normal or corrected-to-normal vision. The participants were tested on three 
different days with a minimum inter-session interval of seven days. Each session lasted 
approximately three hours and the participants were reimbursed 400-500 NOK per session, 
depending on task performance. The experimental procedures were approved by the Regional 
Ethics Committee (2011/1337/REK sør-øst D).  
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Study Design 
The reward responsiveness task was administered as part of a larger psycho-
pharmacological study with several tasks investigating the role of the endogenous opioid system 
in human reward experience and motivation. The tasks involved 1) A reward responsiveness task; 
2) Evaluation of and motivation for receiving soft brush strokes on the forearm; 3) Evaluation of 
and motivation for looking at faces of differing attractiveness; 4) Social decision making with 
money; and 5) Evaluating sweet sucrose solutions. In addition to these tests we collected data 
about subjective experience related to hedonic capacity, mood ratings and possible drug related 
effects at four time points during each session: 1) before drug intake; 2) before testing, 3) during 
testing and 4) at the end of the session. Mid-way through the experiments each session, the 
participants completed a test of motor-coordination. At the end of every session a blood sample 
was collected.  
The study had a repeated-measures within-subject design and was conducted in a double-
blind, placebo-controlled manner. The tasks and the drug order were counterbalanced. At the end 
of session three participants were debriefed and asked to guess the identity of the drug received in 
each session. At the end of data collection, this measure showed that the participants on average 
identified the drug received correctly 34% of the time, indicating a successful blinding of the 
participants. The Reward Responsiveness Task was completed between 70 and 120 minutes after 
drug administration (See Figure 3 for an example of a time line for one participant). The order of 
the tasks was counterbalanced between participants, but did not vary across sessions within-
subject.  
 
 
Figure 3 Outline of an experiment session.  
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Procedures 
Consent and General Instructions.  Prior to the first testing session participants received 
information about the study and a consent form by email. The participants were informed about 
the collection of biological material, i.e. urine- and blood sample. They were asked to sustain 
from eating an hour before testing, and advised not to drive a vehicle for 6 hours after drug 
administration. Further, participants were given brief information about the drugs and possible 
side-effects in the consent form, and were told that they would receive all three drugs in the 
course of three experimental sessions, but that the order would be unknown to them and the 
experimenter.  
Drug administration.  Morphine is a selective µ-opioid receptor agonist. Morphine is the 
most widely chosen analgesic for moderate to severe pain (Vindenes, Handal, Ripel, Boix, & 
Mørland, 2006). In this study we used pills of 10mg morphine (Morfin®, Nycomed Pharma). We 
chose an oral administration as it is less invasive than giving drugs intravenously or 
intramuscularly. The bioavailability of oral morphine is on average 30-40%, but varies 
considerably between individuals. Morphine has maximal effect (tmax) at 1-2 hours after oral 
administration, and a half-life of 2-4 hours (Lugo & Kern, 2002). To minimise subjective effects 
we chose a low dosage of morphine compared to similar studies (Walker & Zacny, 1998; Zacny 
& Lichtor, 2008). Opioids have been shown to interact with female sex hormones at different 
times of the hormone cycle (Ribeiro-Dasilva et al., 2011); for this reason we tested males only in 
this study.   
Naltrexone is a non-selective opioid antagonist with a high affinity to μ- and κ-opioid 
receptors. It is used in the treatment of drug and alcohol addiction to block the effects of 
exogenous opioids (e.g. heroine) or to reduce drug/alcohol craving. Naltrexone acts on the brain’s 
opioid receptors, and therefore also blocks the binding of naturally occurring opioids: endorphins 
(Bachs & Waal, 2002; Bachs & Waal, 2003). The maximal plasma concentration of naltrexone is 
reached after one hour (Verebey, Volavka, Mule, & Resnick, 1976). The half-life of naltrexone is 
described as occurring in three phases: the first three hours; and intermediary phase of 10-12 
hours; and the late phase of 24-72 hours (Verebey et al., 1976). In this study we used pills of 50 
mg naltrexone (Adepend, Orpha-Devel), a standard dosage that has been used with only minor 
side-effects in several previous studies (see reviews by Bachs & Waal, 2002; Yeomans & Gray, 
2002). 
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Placebo pills were cherry-flavoured 
breath mints that were visually matched to 
morphine and naltrexone pills. A small 
amount of the flavoured placebo pills 
were added to the drug dosages, in order 
to avoid any recognition of medication 
taste. The participants were asked to 
swallow, rather than chew, the pills.  
Test Interval. The test interval 
between 1 and 2.5 hours after drug intake 
was deduced by comparing the time of 
maximal bioavailability of oral morphine and 
naltrexone. We also consulted data based on 
measures of morphine and its major 
metabolites in the blood from The Norwegian Institute of Public Health (The Division of 
Forensic Medicine and Drug Abuse Research, see Figure 4).  The maximal plasma concentration 
of both morphine and naltrexone occurs at approximately one hour. While naltrexone levels take 
a long time to decrease, morphine levels decrease quite rapidly, however, morphine levels are 
quite high between 1 and 2.5 hours after oral ingestion. 
Time Line.  After giving written consent, participants were asked to submit a urine sample 
for opiate screening (MOP Opiate300 Test Strip; SureScreen Diagnostics Ltd). After completing 
state-relevant questionnaires, participants received one of three drugs if the drug toxicology was 
negative. To ensure blinding of the experimenter and the participants, the participants were 
instructed not to inspect the drugs visually, but to consume the contents directly from a small 
black box together with some water. 
After drug consumption the participant spent one hour waiting for drug uptake; and were 
given a choice of watching a nature documentary or reading from a selection of magazines. 
Participants were not allowed to bring their own reading material or to work or study while 
waiting for the drug to act.  Sixty minutes after ingesting the drug the participant completed state 
relevant questionnaires before moving on to a different room for testing.  The test session 
Figure 4. Illustration of the plasma concentration of 
morphine after oral administration at different time 
intervals. The shaded area displays the test interval 
chosen for the current study.  
 
The Role of the Opioid System in Reward Responsiveness 
 
16 
 
duration was approximately 80 minutes, and the test order was pseudo randomized and counter 
balanced across participants. 
The Reward Responsiveness Task was completed between 70 and 120 minutes after drug 
administration and always at the same time across sessions within-subject.  
 
Reward Responsiveness Task 
We wished to assess whether the opioid agonist and antagonist would increase and decrease 
(respectively) the degree to which we adapt our behaviour when presented with rewards. To 
achieve this, we adapted a test paradigm used by Diego A. Pizzagalli and his colleagues in a 
series of studies of reward sensitivity in various groups of patients and healthy controls  using a 
range of different methods (Barr et al., 2008; Bogdan & Pizzagalli, 2006; Liu et al., 2011; 
Nikolova, Bogdan, & Pizzagalli, 2012; Pizzagalli, Evins, et al., 2008; Pizzagalli, Iosifescu, et al., 
2008; Pizzagalli et al., 2005; Vrieze et al., 2011). The paradigm was originally developed by 
Tripp and Alsop (1999) to study reward processing in children with attention deficit hyperactivity 
disorder. The test used in the current study resembles the Pizzagalli-lab task more closely both in 
task structure and type of reinforcer (monetary).  
The task, labelled “The Response Bias Probabilistic Reward Task”, measures an 
individual’s tendency to modulate his or hers behaviour as a function of reward. We 
operationalize it as a “measure of reward responsiveness”. In short, this is a signal detection task 
in which the participant is presented with one of two ambiguous stimuli for a very brief time. The 
task is to identify the stimulus using one of two corresponding buttons. A key element of the task 
is that the correct responses can lead to monetary reward, and unknown to the participant, there is 
a differential reinforcement schedule. One of the two stimuli is associated with more frequent 
reward when the correct answer is provided than the other stimulus. The stimulus with high 
reward value is often referred to as ‘rich’ as opposed to the less rewarded ‘lean’ stimulus; I will 
be adopting this terminology for the remainder of the thesis. In this task a correct response to the 
‘rich’ stimulus is rewarded 75% of the time while correct responses to the ‘lean’ stimulus are 
rewarded 25% of the time. This “skewed” reward ratio has been shown to result in a response 
bias, favouring the more frequently rewarded stimulus (Barr et al., 2008; Bogdan & Pizzagalli, 
2006; Liu et al., 2011; Nikolova et al., 2012; Pizzagalli, Evins, et al., 2008; Pizzagalli, Iosifescu, 
et al., 2008; Pizzagalli et al., 2005; Vrieze et al., 2011). In the task used by Pizzagalli and 
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colleagues the participant is presented with a schematic face with no mouth followed by a very 
brief presentation of a short or a long mouth (100ms). The participant’s job is to decide whether 
the mouth presented was short or long, by pressing a corresponding button. The task consists of 
300 trials divided into three equal blocks, the two conditions (e.g. short mouth and long mouth) 
being equiprobable in a random sequence within each block. Incorrect and unrewarded trials 
were followed by a fixation cross.  
 
Task Development. The tasks made to measure reward responsiveness in this study are 
modelled after the task described above, but differ in some aspects. Firstly, we adapted the task to 
suit our cross-over design, with three repeats per participant. Three equivalent stimulus pairs 
were created in order to avoid learning effects across sessions. Test-retest reliability of the 
original task has been assessed by Pizzagalli and colleagues (2005), but the test interval assessed 
(> one month) was much larger than our design allowed. Also, the dimensions of the stimuli used 
in the tests differed slightly as we adapted the task to our test environment, as has been done by 
several other laboratories using this paradigm (Heerey, Bell-Warren, & Gold, 2008; Lee et al., 
2011; Liu et al., 2011). The three versions of the task are identical; the only feature differing is 
the pairs of stimuli (see Figure 5 for an example of a trial). The three versions created for this 
Figure 5. Example of a trial, participants used their dominant hand and the 1 & 2 keys of the 
numpad to respond. 
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study will be referred to as task A, B and C. Stimulus pair A mirrored the original task and the 
mouth was either short or long. In stimulus pair B the mouth appeared slightly to right or the left 
of the middle of the face. Stimulus pair C was slightly angled up towards the left or the right (the 
exact measurements will be described in detail after presentation of the task development 
studies). The stimuli were adapted through the task development phase to ensure that the two 
stimulus alternatives were so similar that it would be difficult to tell the them apart at a brief 
glance, but not impossible. In line with previous studies using this task we opted for an average 
accuracy of 75-85% to ensure that the stimuli were sufficiently ambiguous.  
Three sub-studies were conducted during the task development phase. These studies were 
used to (1) assess whether the three stimuli-pairs were equivalent in difficulty (2) look for 
possible carry-over effects between the sessions, and (3) further adjust the task difficulty.  
(1)Testing the three stimulus pairs. The first versions of the picture pairs were made using 
approximations of stimuli ratios from the studies conducted by Pizzagalli and colleagues. To test 
the three pairs of stimuli, and assess the difficulty level of each task, eight participants (mean age: 
28 years; age range: 22-42) completed 100 trials of each of the three tasks in one session, divided 
into three blocks. In this first investigation the reward schedule was not implemented and a 
fixation cross served as the only feedback. The results showed that all three tasks were too easy 
(see Table 1). One participant reported that the left-right task (B) was very difficult, and indeed 
performed quite poorly (mean accuracy = 61%). The remaining participants had high accuracies 
on all tests. 
Table 1.  
Hit rates for the three tasks  
Stimulus 
pair 
 
Mean hit rate (%) Range (%) 
A 
(short/long) 
92 88-96 
B 
(left/right) 
90 61-100 
C  94 88-97 
 
 The descriptive statistics displayed in Table 1 indicated a ceiling effect, suggesting the 
stimuli were not ambiguous enough. Adjustments were made to all three picture pairs to increase 
the difficulty levels. We also decided that the participants should be seated at a fixed distance of 
80cm distance from the screen. After modifications a more thorough study was conducted in 
order to assess possible carry-over effects between the sessions and to further validate the test 
stimuli with a full-length test.  
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(2) Assessment of test-retest reliability.  Nine 
right-handed men (age range: 20-40 years, mean age: 
29) completed the three tasks (300 trials per session) 
in a pseudo-randomized order, at intervals of one 
week. The participants received reward feedback, 
and also received the total amount of money won at 
the end of session three. In this study we did not 
administer any drugs, given that we wanted to look 
for possible carry-over effects, and further evaluate the 
three stimulus-pairs in order to minimize the differences 
between them.  
Despite the low n, the data was explored, and some analyses were performed to look for 
robust differences. When comparing the three sessions, we found no main effect of session, and 
no trend indicating learning or boredom effects in session 2 and 3 (F(2,22) = 0.345, p = .712) 
compared to the first session. Task equivalence was assessed by using a repeated-measures 
ANOVA of Accuracy for each task type (A, B or C). This revealed a significant main effect of 
task (F(2,48) = 5.977, p = .006). This was due to the fact that task A and B were easier than C 
(see Figure 6). Further, some of the participants in the pilot had very high accuracies (three 
participants had accuracy scores of >93% on all three tests), indicating that the stimuli had not 
been altered enough after the first pilot to avoid a ceiling effect. However, in line with earlier 
results from studies on reward responsiveness, we did find a behavioural preference towards the 
rich stimuli. This preference was reflected in increasing response bias across blocks, higher 
accuracies and shorter reaction times for the rich condition compared to the lean. The findings 
from this study highlighted the necessity to further alter the stimulus pairs, both in order to make 
the differentiation between every two faces more difficult, and to make this differentiation as 
equal in every pair as possible.  
 (3)Manual thresholding study.  Sixteen participants (age range 22-44 years, mean age: 30) 
completed a short version of the experiment, consisting of 100 trials from each of the three tasks 
(A, B, C), divided into three blocks. In this version of the task, the reward feedback schedule was 
implemented; a yellow star with the text “correct!”, but the participants received no money for 
participation. The overall hit rate per block and session was evaluated after every three 
Figure 6.  Average hit-rates for the test-retest  
pilot  study for each task.  
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participants, and the length, angle and positioning of the test stimuli were altered with very small 
adjustments (±~ 0.2 mm). This manual thresholding of the stimuli size ratio was used to make the 
three tasks as equal as possible, and to fit the desired accuracy level of 75-85%. The last six 
participants completed the same task, and none of the participants had hit rates lower than 74% or 
higher than 88% on any of the tasks. Mean accuracy task A: 78%; task B: 80%; task C: 77%: 
These stimulus pairs were used in the final experiment.  
Final task stimuli. The first set of stimuli (Task A) consisted of faces with two horizontal 
lines (mouths) of different length: 11mm and 12mm (0.788 and 0.859 degrees of visual angle 
respectively). This task mirrored the original task developed by Pizzagalli and colleagues, and 
used in previous literature. In the second stimulus-pair (Task B) the positioning of the mouth 
(11.5mm: 0.624 degrees of visual angle) varied along the horizontal axis; and appeared slightly to 
the left or right of the centre. The difference between the two stimuli was 1 mm (0.072 degrees of 
visual angle), each mouth positioned 0.5mm from the centre of the face. In the final pair of faces 
(Task C), the line (11,5mm) was given a slight angle (1 degree) either upwards to the right or to 
the left (see Figure 7 for illustrations of the mouth properties in the three stimulus pairs). The face 
size and eyes were the same across tasks. The face had a diameter of 5.3 cm (degree of visual 
angle: 3.794º), and the person was always sitting 80 cm from the monitor.  
   
Figure 7. Illustration of the stimuli differences. The mouths from each stimulus pair are superimposed on 
each other and inflated. The coloured areas are the overlaps between the two stimuli in pair A and B. 
The angled stimulus pair (C) is demonstrated with a blue and red outline.  
The asymmetric reinforcement schedule applied was identical across the three tasks versions. A 
correct response to a presentation of the rich stimulus meant  a ¾ probability of reward. For the 
lean stimulus the reward probability was ¼. The identity of the stimulus with rich value was 
counterbalanced and randomized across participants. Each session contained 3 blocks of 
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randomized stimulus presentations each consisting of 100 trials. After each block the participant 
had the opportunity to take a short break. The average test duration was 16.4 minutes (range: 15.2 
- 18.9 minutes).  
Instructions.  Before starting the task, the participants were given verbal and written 
instructions about the stimulus properties of the two faces and the corresponding response 
buttons. Ten practice trials (five rich and five lean trials) preceded the test, in which they received 
feedback about their accuracy after each trial, but no money.  Following the practice, the 
participants were instructed that only correct responses could lead to a reward. Further, 
participants were encouraged to try to make as much money as possible by answering quickly 
and accurately. The verbally given instructions were repeated in writing on the computer screen, 
and participants were asked to indicate whether they clearly understood the instructions before 
commencing the task. The participants completed the experiment alone in a lab-room.  
Equipment.  The tasks were presented on a 20" PC monitor with a resolution of 
1600×1200 pixels using E-prime software (version 2.0; Psychology Software tools, Inc, Pittsburg 
Pennsylvania). Participants were positioned in a chair with a neck rest with an 80 cm distance 
from the eyes to the screen.  
 
BRAIN Test 
 To ensure that experiment effects were not due to reduced motor functions in either of the drug 
conditions, the participants completed the BRAIN test (Bradykinesia Akinesia Incoordination 
task, Giovannoni, Van Schalkwyk, Fritz, & Lees, 1999) mid-way through each session. In this 
test participants use their dominant index finger to alternate between two keybord keys, 15 cm 
apart, as quicky and accurately as possible. This test results consist of four indexes of upper limb 
motor function: (1) A kinesia score (KS) which provides the number of keystrokes in 60 seconds; 
(2) an akinesa score (AS): cumulative time the keys a depressed; (3) a dysmetria score (DS) 
providing a weighted score of number of incorrect presses corrected for speed; and (4) an 
incoordination score (IS) a measure of rhythmicity. This test was originally made to assess upper-
limb function in patients with Parkinson’s disease who have dopamine deficiency and motor 
coordination problems. We were primarily interested in assessing the dysmetria score, which is 
an index for overall task performance that takes into account that different people may choose 
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different strategies when completing this test (i.e. prioritizing speed over accuracy or vice versa). 
However, all scores were analysed for drug differences.   
 
Data Analysis 
 Our main dependent variable was the measure of response bias, which was our method of 
assessing reward responsiveness. Based on other studies using this paradigm, we also analysed 
general measures of task performance: discriminability, accuracy and reaction time. 
Discriminability is used in signal detection methodology to assess a participant’s ability to 
distinguish between the stimuli in question. Discriminability is a log transformed accuracy score 
across the two stimulus-types; I have included accuracy as an additional measure only in order to 
assess possible differences in accuracy within the rich and lean condition.  Further, to evaluate 
the general effectiveness of the task in inducing reward responsiveness (overall task 
manipulation), analyses on the placebo condition data are presented before the analyses 
comparing drug conditions.  
 
Variable Computation  
The response bias (log b) was computed using this formula:  
     
 
 
     
                         
                         
  
 
The log b gives us the log transformed ratio of presses on the rich button versus presses on the 
lean button, which can be used as a measure for preference towards the rich stimulus. The 
Response Bias was calculated using mean accuracy scores for each block.  
Discriminability (log d) provides the log transformed ratio of hits and misses, and was 
computed using this formula:   
       
 
 
     
                       
                            
  
 
Percentage values were used in the calculations of response bias and discriminability. To avoid 
log-transformation of scores of zero, 0.5 was added to every cell before calculating the log b and 
log d variables. Finally, accuracy scores for the two stimulus conditions (rich and lean) and 
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reaction time values were considered. These also reflected the behavioural bias towards the most 
frequently rewarded stimulus in previous studies.  
 
ANOVAs 
Overall task manipulation (placebo data) was analysed using repeated-measures ANOVAs.  
Also, for the drug comparison analyses of the secondary dependent variables (Accuracy, 
Reaction Time and Discriminability) were assessed using repeated-measures ANOVAs. 
Statistical Package for the Social Sciences 18 (SPSS INC., Chicago, IL, USA) was used for these 
analyses.   
 
Regression analysis 
We used a repeated measures design in which each participant performed the experiment 
all drug conditions, each time using a different version of the task. Order of drug condition and 
association of drug conditions with task types were counterbalanced or randomized. To test our 
main hypothesis, i.e. the effect of drug on reward responsiveness, we used a multiple linear 
regression model (using MatLab R2011a, Mathworks, Natic, USA).  With a multiple regression 
model the response bias measure can be assessed while modelling out the variance from nuisance 
variables. The multiple regression was set up as a 3 x 3 factorial design of the three drug 
conditions and the three blocks. This design closely resembles a standard repeated-measures 
ANOVA, but permits more flexibility in inclusion of nuisance variables.  Included nuisance 
variables were one dummy variable for each participant to account for differences in overall bias 
in participants, Session number, Task Type, and Discriminabiliy. The 9 main regressors of the 
model allowed us to test the main effects and interactions relevant for our reward responsiveness 
hypothesis by using planned contrasts. Each regressor corresponds to the average response bias 
for a particular block and drug condition (block-wise bias).  Table 2 displays the planned 
contrasts, i.e. comparisons of average effects with 0 or with each other, used to test the 
hypotheses. For each planned contrast t-values were calculated, these were compared with the 
relevant t distributions to test for statistical significance. 
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Table 2. 
Matrix for response bias contrasts.  
Contrast Morphine Placebo Naltrexone Nuisance 
variables  b1 b2 b3 b1 b2 b3 b1 b2 b3 
M > P 1 1 1 -1 -1 -1 0 0 0 0 
P > N 0 0 0 1 1 1 -1 -1 -1 0 
M> N 1 1 1 0 0 0 -1 -1 -1 0 
All b3>b1 -1 0 1 -1 0 1 -1 0 1 0 
Mb3>Mb1 -1 0 1 0 0 0 0 0 0 0 
Pb3>Pb1 0 0 0 -1 0 1 0 0 0 0 
Nb3>Nb1 0 0 0 0 0 0 1 0 -1 0 
Note. M = morphine, P =placebo, N= naltrexone. b = block and numbers signify block.  
 
Results 
Data Exclusion 
Across all participants, two sessions and six blocks were excluded from the analysis due to 
very low hit rates (below chance level), or failure to follow task instructions, i.e. pressing only 
one button for more than 25 consecutive trials, or misidentifying the response buttons (three 
blocks). Further, trials with reaction times shorter than 250 ms or longer than 2500 ms were 
excluded. In addition, for each session, for every subject, trials falling out of range of mean 
reaction time ±3SD (after natural log transformation) were considered as outliers and hence 
excluded from further analysis. Overall, 3.41 % of the remaining trials were excluded. 
Data from the placebo condition were first analysed separately. This was done to ensure 
that our tasks indeed did induce the response bias and that our control data are comparable to 
those of previous studies. Repeated-measures ANOVAs were used. Analyses were conducted on 
the four measures described in the analysis section.  
 
Effects of Task Manipulation  
Response Bias.  In line with previous findings, a one way repeated-measures ANOVA of 
Block on placebo response bias scores showed a main effect of Block F(1.595, 52) =6.699, p = 
.005, partial η2= .205. Contrasts revealed that response bias in block 1, F(1,26) =8.603, p= .007, 
and block 2, F(1,26) =7.418, p=.011, were significantly lower than response bias in block 3 (see 
Figure 8 a). 
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Discriminability. A repeated-measures ANOVA of the discriminability scores per Block 
revealed a significant main effect of Block, F(2, 52) =6.698, p = .004, partial η2= .169. Contrasts 
showed that discriminability in block 1, F(1,26) =10.803, p= .003, and block 2, F(1,26) =5.409, 
p=.028, were significantly lower than discriminability in block 3 (see Figure 8 b)  
 
 
 
Accuracy.  A two-way repeated measures ANOVA of Block × Stimulus Condition (rich 
and lean) for the placebo accuracy data only revealed significant main effects of Block 
(F(2,52)=6.411, p= .003, η2= .198) and Stimulus Condition (F(1,26)=20.091, p= .000, partial 
η2= .436).  Replicating findings from earlier studies, the interaction of Block × Stimulus 
Condition was also significant F(2,52) = 6.715, p= .005, partial η2= .205. Separate ANOVAs for 
each stimulus level indicated that the interaction was due to a significant decrease in lean 
accuracy in from block 1 to block 3. There was no significant difference in rich accuracy across 
blocks (see Figure 9 a).  
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Figure 8. Mean response bias (a) and discriminability (b) per block in the placebo condition.  Error bars 
show standard error of the mean. 
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Reaction Time.  The ANOVA on  Reaction Time data of Block × Stimulus Condition revealed 
main effects of Block F(2,52)=3.557, p= .038, partial η2= .120) and Stimulus Condition 
(F(1,26)=14.104, p= .001, partial η2= .352).  However there was no significant interaction, i.e. no 
significant increase in this difference over the course of the three blocks.  
Together, the accuracy and reaction time results indicate that the task induces a behavioural 
preference towards the rich stimulus; the participants correctly identify the rich stimulus more 
often than the lean, and that they respond faster to it.   
 
Effects of Drug Manipulation 
Response Bias. The main effects of interest were the contrasts that allowed us to assess 
(a) whether there are significant differences in the degree of Response Bias between the three 
drug conditions; (b) whether there is an increase in Response Bias across the three blocks; and 
(c) whether the pattern of increase in bias was different between in the three drug conditions. The 
planned contrasts showed that the bias in the morphine condition was significantly higher than 
bias induced in the placebo and naltrexone conditions. Further, the overall bias was significantly 
lower in the naltrexone condition than in both placebo and morphine conditions (see Figure 10 
and Table 3). The R
2
 for the model was .4305, adjusted R
2
= .3166 (see Table 3 for statistics).  
Figure 9. (a) Mean accuracy for and (b) mean reaction time for the rich and lean stimuli in the placebo 
condition. Error bars show standard error of the mean.  The asterisks ** represent p-values <.01 and 
refer to the contrast of the difference between rich and lean in block 1 versus block 3. 
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Table 3.  
Planned contrasts of Response Bias in all Drug conditions and Beta values for the Task and Session 
regressors. 
Contrasts  Standardized Coefficients  
 β Std. Error t p 
Morphine > Placebo 0.089 0.0139 6.37 <0.0001 
Morphine > Naltrexone 0.234 0.0144 16.24 <0.0001 
Placebo > Naltrexone 0.145 0.0145 10.01 <0.0001 
Nuisance regressors   
    
Task A – Task C 0.0029 0.0288 0.10 0.9194 
Task A – Task B 0.0143 0.0280 0.51 0.6102 
Session 1 – Session 2 0.0750 0.0279 2.68 0.0078 
Session 1 – Session 3 0.0165 0.0282 0.58 0.5600 
Model R2 = .4181, Adjusted R2 =.2982, F(41,199)= 3.7362 , p < .0001 
Note.  Standardized values are shown:  β values, Standard error of the mean, t-statistic and significance 
level (respectively).   
 
Response bias over time. The planned contrasts in the multiple regression revealed a 
significant increase in overall response bias regardless of drug condition from block 1 to block 3 
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Figure 10. Adjusted Beta-values from the GLM for the bias in each drug 
condition. *** = p values lower than .0001. Significance value notations refer to 
drug-specific contrasts shown in Table 3. 
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(see Table 4). Contrasts for each drug condition separately showed that the increase in bias from 
block 1 to block 3 was only significant for the placebo condition. We ran a post hoc contrast to 
see whether the response bias was significantly higher in block 1 for morphine than placebo, - 
this was confirmed (see Figure 11 and Table 4).  Response bias was high in block 1 of the 
morphine condition and remained high throughout the task.  
Table 4  
Planned and post hoc contrasts for block-wise bias scores.  
Contrasts Standardized Coefficients 
 β       Std. Error t           p 
Overall: Block 3 > Block 1 0.052 0.0142 3.65 <0.0001 
Morphine: b3 > b1 -0,0080 0,0078 -1,0242 0.3069 
Placebo: b3> b1 0,0681 0,0080 8,4881 <0.0001 
Naltrexone b3 > b1 -0,0067 0,0082 -0,8116 0.4180 
M1 > P1* 0.049 0.008 6.18 <0.0001 
Note. Standardized values are shown:  β values, Standard error of the mean, t-statistic and significance 
level (respectively). M= morphine, P=placebo and numbers signify block.  * A contrast of special interest, 
testing whether the difference between response bias in block 1 was significantly higher than response 
bias in block 1 for the placebo condition.  
 
 
Figure 11. Response bias per block and drug. Numbers on the Y-axis are the adjusted Beta weights from 
the multiple correlation. 
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Accuracy.  As expected from the uniform findings in earlier studies, a repeated-measures 
ANOVA on accuracy data of Drug × Stimulus Condition revealed a significant main effect of 
stimulus condition (F(1,25)= 36.712, p < .0001, η2 = .595). The main effect of drug condition 
was not significant, but the linear contrast did approach significance (F(1,25) = 3.810, p =.062, 
partial η2 = .132) Indicating that accuracy in the morphine condition was somewhat higher than 
accuracy in the placebo condition and that accuracy for the placebo condition was higher than the 
accuracy for the naltrexone condition (see Figure 12 a). Separate ANOVAs for each stimulus 
condition showed a significant main effect of drug for the rich stimuli accuracy F(2,50)= 3.853, 
p= .028, partial η2=.134. The linear trend for rich stimulus accuracy was also significant 
F(1,25)=8.830, p=.006, partial η2=.261 (see 12 a). There was no significant effect of drug on 
accuracy in the lean condition.  
Reaction Time.  A repeated-measures ANOVA of reaction time data on Drug × Block × 
Stimulus Condition showed a significant main effect of stimulus condition (F(1,20) = 20.498, p < 
.0001, partial η2=.506) (see Figure 12 b) and a main effect of block (F(2,40)= 8.805, p =.002, 
partial η2 = .306). The interaction between drug and stimulus reaction time was not significant.  
 
Discriminability A two-way repeated measures ANOVA of drug x block on the log d 
scores revealed no significant main effect of drug, F(2,40) = .924, p=.390, η2= .045). There was 
however a significant main effect of block, F(2,40) = 7.085, p=.004, η2= .262. Contrasts showed 
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Figure 12. Graph of Rich and lean reaction time data for each drug condition. Rich values are 
illustrated with strong colours and displayed first in the pair of columns. Mean accuracy for the 
rich and lean stimulus condition for each drug. Rich stimuli accuracy is depicted in strong colours 
and lean in a lighter shade. Error bars show standard error of the mean.  ** signify p < .01 and 
refers to the main effect of drug on rich accuracy.    
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that this was due to a decrease in discriminability from block 1 to block 3 (F(1,29)=9.654, 
p=.006, η2= 326. Separate ANOVAs for each drug condition showed that the main effect of block 
on discriminability was only significant for the placebo condition (see overall task manipulation 
section).  
Task and Session. Data from the regression model allowed us to assess whether the two 
new task types (B and C) contributed significantly less or more to the response bias than the 
original short-long task (A) from which the tasks were adapted. Neither of these turned out to be 
significant contributors to the response bias (Task B: β = .0029, p = .9195; Task C β = .0143, p = 
.6103). The β weights reflecting the contribution of session order (session 2 and 3 compared to 
session 1) showed that session 2 (β = .0750, p = .0078), but not session 3 (β = .0165, p = .5600) 
contributed significantly to the response bias.  
 
BRAIN 
The repeated-measures ANOVAs for the four measures of motor coordination showed no 
significant effects of drug.  Dysmetria:   F (1,25) = .037, p < .964, η2= .003. Kinesia:  F (1, 25) = 
.128, p < .881 η2= .011 Incoordination:   F (1,25) = .155, p < .857, η2= .013 Akinesia:   F (1,25) = 
2.404, p < .112, η2= .167. These results indicate that the differences in performance on the test 
across drug conditions were not due to significant decreases in motor or eye-hand coordination.  
 
Discussion 
We measured reward responsiveness in thirty healthy male participants across three 
different drug conditions (morphine, naltrexone and placebo) to investigate whether reward 
responsiveness is modulated by systemic opioid manipulation. We predicted a linear relationship 
between the drug conditions, with opioid agonist treatment leading to higher reward 
responsiveness than the placebo condition, and opioid antagonist treatment causing lower reward 
responsiveness than the placebo treatment. This hypothesis was supported by the results from our 
regression analysis of response bias. In addition to our reward responsiveness measure, the 
analysis of the accuracy in the rich condition across drugs confirms a stronger preference towards 
the most frequently rewarded stimuli in the morphine condition compared to naltrexone.  In line 
with previous findings (Pizzagalli, Evins, et al., 2008) we found no significant differences in 
reaction time and discriminability measures between the three drug conditions.  The results for 
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the placebo condition alone show that the tasks modified for this study successfully induced the 
response bias found in earlier studies using this paradigm. These results give reason to believe 
that we can validly compare the effects of our measures across the drug conditions. Also, the 
analyses of motor-coordination showed that motor abilities were not significantly different across 
drug conditions. 
The reward responsiveness task does not allow us to dissociate between the three reward 
components proposed by Berridge (Berridge, 1996; Berridge & Robinson, 1998). The process 
mediating reward responsiveness is likely to involve all three reward components (i) hedonic 
evaluation of the reward; (ii) prediction and anticipation of a reward following a given choice and 
(iii) association learning of the reward information following a trial, and updating this association 
as the task progresses and the information on which to base a decision increases. These constructs 
are however useful for interpreting the results and hypothesizing about the underlying 
mechanisms of the results.  
Indirect dopamine modulation of reward responsiveness? The drug effects found in the 
current study could be caused by several different mechanisms .The involvement of the 
dopaminergic system in reward related processes is well documented and two studies have 
assessed DA involvement in this paradigm specifically (Pizzagalli et al., 2008; Vrieze et al., 
2011). Systemic opioid manipulation has been shown to modulate the release of DA in the brain 
via GABAergic mechanisms (Corbett, 2006). It is therefore possible that systemic agonism of the 
opioidergic system could have an indirect effect on reward responsiveness by increasing the 
endogenous DA transmission during the task. The opposite effect could be elicited by opioid 
antagonism with naltrexone, namely an inhibition of DA transmission between the VTA and the 
NAc by increasing GABAergic activity in the VTA (Johnson & North, 1992; Nestler, 2005). If 
the observed drug effects on reward responsiveness are due to DA increase and decrease, we 
could hypothesize that they are due to enhancement and reduction of DA dependent motivational 
or ‘wanting’ aspects of the reward process as proposed by Berridge, Robinson and colleagues 
(Berridge, 2007; Robinson et al., 2005). On the other hand, DA modulation may also have 
directly affected the efficiency of positive reinforcement learning (Schultz, 2010). There is 
evidence to support the role of dopamine reinforcement learning in humans and animals, in 
particular when it comes to learning from positive reinforcement (Ljungberg et al., 1992; 
Pessiglione, Seymour, Flandin, Dolan, & Frith, 2006; Stevenson et al., 2006). The current data 
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also align with a previous study using the same reward responsiveness paradigm to test the 
influence of a polymorphism of the µ-opioid receptor gene (OPRM1) on reinforcement learning 
(Lee et al., 2011). Notably, the authors of this study interpreted their findings as due to an indirect 
effect of MOR-availability on dopaminergic mechanisms.  
Direct opioid modulation of reward ‘liking’?  As outlined in the introduction, opioidergic 
modulation has been shown to influence the positive affective evaluation of natural rewards 
(Dreher, 2009; Langleben, Busch, O'Brien, & Elman, 2012; Peciña & Berridge, 2000; Yeomans 
& Gray, 1996), a process that may be independent of dopaminergic processes (Cannon & 
Palmiter, 2003). The observed increase in reward responsiveness in the morphine condition may 
be partly due to direct modulation of opioids on the ‘liking’ of the reward, i.e. the positive 
affective reaction. If this is the case, the bias is modulated by the subjective hedonic value that 
the ‘reward message + monetary reward’ has for the participant during the task in the different 
drug conditions. According to Berridge (2003), this type of hedonic modulation would not need 
to be consciously explicit for the agent. Nonetheless, systemic administration of MOR agonists 
has been shown to increase subjective rating of well-being/euphoria (Becerra et al., 2006; 
Vaupel, Lange, & London, 1993). Using pharmacological fMRI study Petrovic et al. (2008) 
found naloxone attenuation of pleasure ratings of larger rewards (compared to a relatively small 
reward), lending support to the idea of opioid modulation of subjective pleasure experience of a 
given reward. Also, studies using opioid-antagonism have demonstrated reduction in euphoria 
measures (Hollister, 1981; Janal, Colt, Clark, & Glusman, 1984).  Furthermore, increased 
endorphin levels have shown to correlate with measures of euphoria on a conscious level in 
human beings (Boecker et al., 2008; Koepp et al., 2009). Increased ‘liking’ of the reward could 
thus be a result of mood modulation related to opioid manipulation. These findings collectively 
suggest a key role for the opioid system in subjective well-being.  
The drug effect presented here, showing morphine up-regulation and naltrexone reduction 
of reward responsiveness, could also be facilitated by a combination of several processes.  It is 
possible that the effects are partly dopamine mediated via GABA perhaps affecting wanting and 
learning aspects required by the task, and partly caused by direct opioid modulation of reward 
value.  
Are opioids necessary for or merely involved in reward responsiveness? In order to answer 
this question based on a data from a pharmacological study, it is crucial whether one can 
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efficiently block the entire population of receptors in question or not. The most cited study on 
receptor occupancy by oral naltrexone was conducted by Lee et al., in 1988. They used a 
radioactive ligand ([
11
C]Carfentanil) to investigate the MOR availability after a single dosage of 
50mg naltrexone in healthy participants at different time points. Their results showed a µ-
receptor blockade of 91 ± 6 % 48 hours after oral naltrexone administration, and a maximum 
blockade at one hour post drug ingestion. The authors conclude that 50mg of naltrexone is more 
than what it needed to block the opioid receptors. The high receptor occupancy at 48 hours post 
administration indicated that a complete blockade at the time of our experiment (1-2.5h) is very 
likely. Unfortunately, the study does not report measures of receptor blockade at one hour. The 
efficacy of naltrexone in blocking opioid receptors is also demonstrated in a study using an 
agonist challenge (hydromorphone)(Schuh, Walsh, & Stitzer, 1999). In this study oral naltrexone 
25mg completely blocked the effects of the agonist challenge.  
If opioids are necessary for the modulation of behaviour as a function of reward outcomes, 
and naltrexone (50 mg) results in a complete blockade of endogenous opioid signalling, we might 
expect that a naltrexone blockade of endorphins would abolish this effect completely, and result 
in no bias at all. What we observe in the current study is that response bias is blunted, or down-
regulated, but does not disappear.  
Enhanced speed of reinforcement learning by µ-opioid agonism? A curious finding from 
our study is the speed at which the participants acquire a high response bias in the morphine 
condition. The participants develop a high bias during block one in the morphine session, and 
maintain this level of preference for the rich stimulus across the remainder of the experiment. 
One possible interpretation for this is that opioid agonism may induce a primacy effect of reward 
when morphine is involved. The probability of the first reward following a “rich face” is 75 per 
cent. Of interest in relation to this effect, a reinforcement model put forward by (Frank, 2005) 
posits  that phasic dopamine bursts during positive feedback strengthen the chosen response, 
which in turn promotes learning of this stimulus-response link that was followed by a positive 
reinforcer. If morphine indeed increases or potentiates the phasic dopamine bursts, this may 
explain the rapidity of the response bias development in this drug condition.  
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Limitations 
We did not directly control, or monitor, central dopaminergic neurotransmission, nor any 
other neurotransmitter systems in this study. Therefore we can only hypothesize about the 
possible interactions of different neuromodulator systems in the reward responsiveness effect. 
Also, we cannot be sure that there are no brain compensatory mechanisms that are in play when 
one transmitter system is ‘down’ due to antagonist treatment (Cannon & Palmiter, 2003).  This 
thesis has exclusively focussed on the opioidergic and dopaminergic neurotransmitter systems, 
with a reference to GABAergic mechanisms. This choice is not due to their unique roles for 
reward-related processes, but rather owing to a major focus on these two transmitters in this line 
of research (Kranz et al., 2010). Substances such as serotonin, norepinephrine, cannabinoids, and 
glutamate are some of the neurotransmitters found to play a role in reward although the 
involvement of these are not well understood yet in humans (Harley, 2004; Kranz et al., 2010; 
Palminteri, Clair, Mallet, & Pessiglione, in press).  
While we used a selective MOR agonist, the antagonist naltrexone was a non-selective 
opioid antagonist that also binds to κ- and to some extent δ-opioid receptors. Different, and 
sometimes competing, functions have been found for these different receptor types. (Taha et al., 
2006) There are no viable oral options for blocking µ-opioids selectively as of today. 
Nevertheless, naltrexone has high affinity to µ-receptors, and the dosage used in the current study 
is likely to have had a complete, or very high blockade of this receptor. µ-opioid involvement is 
further supported by the opposite effects we have observed on response bias by agonist and 
antagonist treatment.  
By Carrot-or-stick? In the current experiment we only assessed the effect of positive 
reinforcement on behaviour. Our study did not address how an opioidergic agonist and antagonist 
manipulation would affect our behavioural response to negative reinforcement, as has been done 
in some other studies (Frank et al., 2004; Pessiglione et al., 2006; Petrovic et al., 2008). 
Pessiglione and colleagues (2006) tested healthy participants treated with DA enhancing or 
reducing drugs on a probabilistic decision task with rewards and losses. Interestingly, they found 
an asymmetric effect of drug on gain and loss conditions, indicating a special role for dopamine 
in positive reinforcement. It would be interesting to test the effect of opioid agonism and 
antagonism on learning from negative reinforcement. 
The Role of the Opioid System in Reward Responsiveness 
 
35 
 
We found decreased discriminability across the three blocks in the placebo condition. This 
has not been reported in earlier studies using this task. The discriminability measure is assumed 
to reflect task performance, indicating ability to distinguish between the different stimuli but also 
possible failure to attend to the stimuli (Tripp & Alsop, 1999). However, response bias and 
discriminability scores are not independent of each other, and a high log b score can decrease the 
log d measure (Klein, 2001). This indicates that the discriminability effect need not be interpreted 
solely as a declined ability in telling the stimuli apart, but rather as an effect of a strong bias 
leading to more frequent misidentification of the lean stimulus. However, discriminability was 
included as a factor in our regression model, which allowed us to model out the variance due to 
differences in task performance. 
 
Implications  
Deficits in reward processing.  Reward responsiveness has been studied in several clinical 
populations. Symptoms of depression are correlated with a reduction in reward responsiveness in 
a group of healthy volunteers (Pizzagalli et al., 2005). In a subsequent study a group of 
individuals diagnosed with major depressive disorder (MDD) was shown to have reduced reward 
responsiveness compared to a matched group of healthy controls (Pizzagalli, Iosifescu, et al., 
2008).  Also patients with bipolar disorder (BPD) in a euthymic state (Pizzagalli, Goetz, et al., 
2008) and children with attention deficit hyperactivity disorder (ADHD)(Tripp & Alsop, 1999) 
show reduced reward responsiveness. Reduced reward responsiveness can be an indicator of 
anhedonia; a symptom associated with MDD and BPD, which refers to a reduction or inability to 
experience pleasure (Der-Avakian & Markou, 2012). An understanding of the neural 
underpinnings of anhedonia may lead to better understanding of disorder that effect reward 
mechanisms, and may be used to make treatments for the symptom. To my knowledge, only one 
other study using this paradigm has shown enhancement of reward responsiveness. In this study, 
the effect of nicotine in non-smokers on reward responsiveness was tested with and without 
nicotine, revealing an increased bias in the nicotine condition (Barr et al., 2008). Curiously, and 
contrasting earlier studies, the control condition in this study did only induce a very small 
response bias. Response bias reduction has been found in some psychopathologies, in response to 
stress and with dopamine antagonism. It would be interesting to see whether opioid agonism 
could reverse the ‘reward responsiveness deficit’ in clinical populations. It would also be 
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interesting to know whether this reward responsiveness reduction can be inversed by standard 
pharmacological treatments for MDD, such as selective serotonin reuptake inhibitors (SSRIs).  
There are still many questions left to answer in the quest for a better understanding of 
psychological and neural aspects of reward. Nevertheless, such knowledge may be crucial for 
elucidating the ontology of excessive reward seeking and consumption (or lack there-of) 
underlying several psychopathologies (e.g. major depressive disorder, sex-, food-, and gambling 
disorders). Opioid-reward directed research has already led to some successful opioid antagonist 
treatment studies. Grant, Suck, and Hartman (2008) used naltrexone to treat patients who suffered 
from pathological gambling and Drewnowski et al. (1995) found naloxone attenuation of binge 
eating. Naltrexone has also been shown to be successful in the treatment of alcohol dependence 
(Volpicelli, Alterman, Hayashida, & O'Brien, 1992). 
In addition to being relevant for the understanding of reward-related psychopathology, 
gaining a better understanding of the mechanisms behind what drives us to act and makes us feel 
good has inherent value.   
 
Conclusion 
The current study replicates findings from animal research revealing an important role for the 
opioid system in reward-related behaviour. Systemic manipulation of the opioidergic system 
modulates reward responsiveness in healthy young men. Morphine enhances, and naltrexone 
diminishes, this effect compared to a placebo control condition. The naltrexone condition did not 
eliminate the response bias, which implies that endogenous opioids are involved in, but may not 
be necessary, for the mediation of reward responsiveness. Although the exact neural mechanism 
that mediates this effect cannot be elucidated by the current experiment, findings from animal 
research indicate that the effect could be either dopamine mediated or directly mediated by µ-
opioids. Although little is known about the role of the human opioid system for related reward 
processes, findings from this study argue for a significant role for the µ-opioid system in 
mediating reward responsiveness.  
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